Chansik An

Yonsei University — South Korea

Medicine · Health Sciences

28h-index2.6kcitations110works1.62yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Hepatocellular Carcinoma Treatment and Prognosis(44), Liver Disease Diagnosis and Treatment(29), Radiomics and Machine Learning in Medical Imaging(24), MRI in cancer diagnosis(15), Cholangiocarcinoma and Gallbladder Cancer Studies(14)

Publications110 total

Biology-driven stratification of advanced biliary tract cancer treated with nab-paclitaxel plus gemcitabine–cisplatin: A prospective observational cohort study
Hepatology·2025· 1 citedOpen Access
Differential implications of tumor endothelial cell and lymphocyte densities in advanced hepatocellular carcinoma patients treated with immunotherapy
npj Precision Oncology·2025Open Access
Pathologist-Artificial Intelligence Concordance in HER2 Interpretation for Advanced Biliary Tract Cancer: Intraobserver, Interobserver, and Human-Artificial Intelligence Variability
Laboratory Investigation·2025
Integrative multi-omics profiling identifies infiltrative hepatocellular carcinoma as an immunotherapy-resistant subtype with distinct molecular features
Clinical and Molecular Hepatology·2025· 2 citedOpen Access
1490P Infiltrative HCC defines a clinically and molecularly distinct subtype with poor clinical outcomes from atezolizumab plus bevacizumab
Annals of Oncology·2025
Organ‐Specific Responses to Nivolumab Plus Ipilimumab in Advanced Hepatocellular Carcinoma: A Multicenter, Retrospective Study
Cancer Medicine·2025Open Access
Prognostic Significance of Volumetric Parameters on Pretreatment FDG PET/CT in Patients With Hepatocellular Carcinoma Receiving Atezolizumab Plus Bevacizumab Therapy
Clinical Nuclear Medicine·2025· 4 cited
OP02-3 Ipilimumab and nivolumab in advanced hepatocellular carcinoma after failure of prior atezolizumab and bevacizumab treatment: A multicenter retrospective study
ESMO Open·2025· 1 citedOpen Access
Diagnostic cholangioscopy for surgical planning of extrahepatic cholangiocarcinoma
Scientific Reports·2025Open Access
Nivolumab plus ipilimumab in advanced hepatocellular carcinoma with Child-Pugh B: A multicenter retrospective study.
Journal of Clinical Oncology·2025
Organ-specific responses to nivolumab plus ipilimumab in patients with advanced hepatocellular carcinoma: A multicenter, retrospective study.
Journal of Clinical Oncology·2025
Noncontrast Magnetic Resonance Imaging vs Ultrasonography for Hepatocellular Carcinoma Surveillance: A Randomized, Single-Center Trial
Gastroenterology·2025· 13 cited
Association between incidental perirenal fat stranding on CT and metabolic syndrome in otherwise healthy adults
La radiologia medica·2024· 1 cited
910P Multi-omics analysis of tislelizumab plus nab-paclitaxel and cisplatin as neoadjuvant immunochemotherapy for locally advanced hypopharyngeal squamous cell carcinoma: A prospective single-arm phase II trial
Annals of Oncology·2024
946P Ipilimumab and nivolumab in advanced hepatocellular carcinoma after failure of prior atezolizumab and bevacizumab treatment: A multicenter retrospective study
Annals of Oncology·2024Open Access
Genomic and transcriptomic biomarkers of nab-paclitaxel plus gemcitabine-cisplatin in patients with advanced biliary tract cancer.
Journal of Clinical Oncology·2024
Distinct Characteristics and Changes in Liver Function of Patients with Hepatocellular Carcinoma Treated with Atezolizumab Plus Bevacizumab for More Than 1 Year
Cancer Research and Treatment·2024· 7 citedOpen Access
Additional nodules detected using EOB-MRI in patients with resectable single hepatocellular carcinoma: an implication for active treatment strategy
Journal of Liver Cancer·2024· 1 citedOpen Access
Distinct characteristics and changes in liver function of patients with HCC treated with Ate/Bev for more than 1 year
Research Square (Research Square)·2024Open Access
Artificial intelligence (AI)-powered tumor microenvironment (TME) analysis to identify potential biomarkers for ICIs with or without bevacizumab in hepatocellular carcinoma (HCC).
Journal of Clinical Oncology·2024· 1 cited
page 1 of 6Next →

Frequent Co-authors

Myeong‐Jin Kim(29), Kyunghwa Han(11), Jin‐Young Choi(10), Sung Soo Ahn(9), Mi‐Suk Park(9), Seung‐Koo Lee(8), Hyungjin Rhee(6), Sumi Park(6), Do Young Kim(6), Yong Eun Chung(5), Yae Won Park(5), Young Nyun Park(4), Yeun‐Yoon Kim(4), Hwiyoung Kim(4), Kwang‐Hyub Han(4), Huapyong Kang(4), Jung Hyun Jo(4), Moon Jae Chung(4), Jeong Youp Park(4), Si Young Song(4)